News | February 05, 2024
KIMS posts Q3 FY24 consolidated PAT at Rs. 71.84 Cr
KIMS has reported total income of Rs. 609.091 crores during the period ended December 31, 2023
KIMS has reported total income of Rs. 609.091 crores during the period ended December 31, 2023
Delivers keynote address at the 4th convocation of AIIMS Jodhpur
Indian Pharma Post brings together the views of industry leaders on the Interim Union Budget 2024-25 announcement and its impact on the industry
Revenue from Operations stood at Rs. 2,607 crore, 25% YoY growth. Domestic revenue at Rs. 2,400 crore, 20% YoY growth and export revenue at Rs. 207 crore, 118% YoY growth
Developed by Pfizer, Abrocitinib has received marketing authorization from the Central Drugs Standard Control Organization (CDSCO) in India
Exblifeb demonstrates remarkable efficacy in treating complicated Urinary Tract Infections (cUTI), pneumonia
About 75% of all primary liver cancers in adults are HCC and up to 30% of HCC patients are eligible for embolisation
Submission to be reviewed under FDA real-time oncology review and Project Orbis
Union Ayush Minister with Assam Chief Minister lays foundation stone for Central Research Institute of Yoga & Naturopathy
This alliance brings together drug innovation capabilities of Glenmark and Ichnos to develop cutting-edge therapies for the treatment of hematological malignancies and solid tumors
Subscribe To Our Newsletter & Stay Updated
